Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion type Assertion NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_head.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion evidence source_evidence_literature NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion SIO_000772 10883674 NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion wasDerivedFrom befree-20150227 NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion wasGeneratedBy ECO_0000203 NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.